Update on Biomarkers of Hepatocellular Carcinoma Roongruedee Chaiteerakij, Benyam D. Addissie, Lewis R. Roberts  Clinical Gastroenterology and Hepatology  Volume 13, Issue 2, Pages 237-245 (February 2015) DOI: 10.1016/j.cgh.2013.10.038 Copyright © 2015 AGA Institute Terms and Conditions

Figure 1 Applications of established and novel HCC biomarkers in clinical care. Clinical Gastroenterology and Hepatology 2015 13, 237-245DOI: (10.1016/j.cgh.2013.10.038) Copyright © 2015 AGA Institute Terms and Conditions

Figure 2 Performance of AFP, AFP-L3%, and DCP for early HCC diagnosis in patients with cirrhosis. AUC, area under the curve. Clinical Gastroenterology and Hepatology 2015 13, 237-245DOI: (10.1016/j.cgh.2013.10.038) Copyright © 2015 AGA Institute Terms and Conditions

Figure 3 Arterial-phase computed tomography image of a large HCC tumor shown to have FGF3/FGF4 amplification before sorafenib treatment (A). After treatment with sorafenib for 2 months, the tumor size was substantially decreased as shown in the arterial phase (B) and hepatocyte phase (C) magnetic resonance images. (Panel A reproduced with permission from Arao T et al. FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma. Hepatology 2013;57:1407-1415; Panels B and C courtesy of Dr Masatoshi Kudo, used with permission) Clinical Gastroenterology and Hepatology 2015 13, 237-245DOI: (10.1016/j.cgh.2013.10.038) Copyright © 2015 AGA Institute Terms and Conditions